Des Plaines Clinical Lab INC

Des Plaines Clinical Lab INC was paid $25.51M by Medicaid between Jan 2018 and Dec 2024, across 165 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 15% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Illinois

Rank by total paid#6 of 235

Median peer was paid$123K

This provider vs. median208×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	144,677	$2.41M
2019	167,873	$3.51M
2020	243,951	$5.02M
2021	195,244	$4.52M
2022	214,621	$4.82M
2023	150,757	$2.71M
2024incomplete	143,585	$2.51M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	15%	55,004	44,322	$3.86M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	13%	38,137	31,431	$3.28M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	11%	75,363	61,347	$2.81M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	5.2%	21,253	18,910	$1.33M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	3.8%	44,503	36,359	$978K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	3.5%	9,870	7,659	$887K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	3.4%	19,883	16,811	$860K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	3.0%	36,120	28,402	$767K
84443	Thyroid stimulating hormone (TSH)	2.8%	49,737	39,466	$709K
83970		2.0%	18,560	14,960	$506K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	2.0%	13,147	9,741	$501K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	2.0%	3,230	2,425	$501K

153 more codes

87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.9%	13,052	$497K
80053	Comprehensive metabolic panel	1.9%	56,661	$495K
83021		1.9%	45,153	$485K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.5%	41,638	$390K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.3%	61,049	$331K
86141		1.2%	21,235	$304K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	1.2%	12,316	$304K
84439		1.2%	39,193	$304K
82607		1.2%	29,257	$302K
86480		1.1%	7,572	$291K
86481		1.0%	5,325	$259K
82728		<1%	37,574	$250K
80061	Lipid panel	<1%	48,108	$244K
82746		<1%	22,169	$222K
87902		<1%	1,736	$222K
84480		<1%	21,533	$180K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	1,810	$167K
84466		<1%	19,974	$154K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	3,589	$148K
83735		<1%	22,522	$129K
83540		<1%	23,393	$128K
86769		<1%	2,644	$112K
83690		<1%	18,589	$108K
87086	Culture, bacterial; quantitative colony count, urine	<1%	12,628	$102K
86803		<1%	7,534	$101K
82150		<1%	18,080	$100K
83009		<1%	2,347	$83K
86705		<1%	6,340	$78K
86696		<1%	5,169	$77K
85651		<1%	18,953	$77K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	1,277	$75K
81001		<1%	29,879	$71K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	<1%	1,950	$68K
82977		<1%	17,851	$68K
87481		<1%	1,386	$67K
87632		<1%	449	$66K
86695		<1%	5,683	$64K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	1,654	$63K
84100		<1%	16,420	$57K
82533		<1%	4,828	$54K
80074		<1%	1,891	$52K
87390		<1%	2,563	$52K
87391		<1%	2,566	$51K
84153		<1%	4,592	$50K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,982	$47K
87641		<1%	1,816	$44K
87341		<1%	4,730	$42K
87640		<1%	1,766	$41K
87581		<1%	1,641	$41K
86706		<1%	3,675	$41K
87486		<1%	1,634	$40K
86704		<1%	3,082	$38K
87541		<1%	1,413	$33K
80050	General health panel	<1%	2,445	$32K
87500		<1%	1,840	$30K
86701		<1%	2,601	$29K
36415	Collection of venous blood by venipuncture	<1%	20,370	$26K
86708		<1%	3,090	$24K
87653		<1%	1,346	$24K
86702		<1%	2,599	$23K
86709		<1%	4,531	$21K
86593		<1%	6,214	$21K
82043		<1%	6,435	$21K
87507		<1%	68	$21K
84550		<1%	6,589	$20K
87186		<1%	2,963	$20K
83036	Hemoglobin; glycosylated (A1C)	<1%	3,692	$19K
82570		<1%	4,452	$17K
87340		<1%	1,718	$17K
86592		<1%	5,641	$17K
86431		<1%	2,840	$15K
87529		<1%	460	$14K
83655		<1%	1,416	$14K
87081		<1%	2,012	$14K
82550		<1%	3,418	$13K
86677		<1%	1,174	$12K
84460		<1%	3,812	$12K
84481		<1%	1,495	$11K
85730		<1%	1,722	$9K
84436		<1%	7,934	$8K
86038		<1%	765	$8K
85610		<1%	2,262	$8K
82565		<1%	2,719	$8K
84403		<1%	371	$7K
87150		<1%	822	$7K
86003		<1%	232	$6K
87511		<1%	314	$6K
87563		<1%	374	$6K
83001		<1%	342	$5K
84155		<1%	2,306	$5K
85652		<1%	2,358	$4K
84110		<1%	1,168	$4K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	291	$4K
84702		<1%	532	$4K
87077		<1%	4,182	$4K
80048	Basic metabolic panel (calcium, ionized)	<1%	534	$4K
83550		<1%	709	$4K
84703		<1%	583	$3K
87075		<1%	263	$3K
83002		<1%	336	$3K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	1,474	$2K
84146		<1%	221	$2K
86343		<1%	269	$2K
82542		<1%	248	$2K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	57	$2K
86235		<1%	159	$2K
87631		<1%	19	$2K
80305		<1%	261	$2K
84105		<1%	548	$2K
87634		<1%	51	$1K
82784		<1%	109	$1K
82042		<1%	334	$1K
86762		<1%	180	$1K
82785		<1%	216	$1K
86735		<1%	116	$1K
84600		<1%	267	$1K
86060		<1%	234	$1K
86765		<1%	152	$1K
84450		<1%	306	$1K
84165		<1%	102	$976.29
82540		<1%	420	$958.15
85045		<1%	461	$899.64
84154		<1%	95	$869.38
87071		<1%	123	$566.24
85660		<1%	132	$546.94
83986		<1%	248	$522.86
83013		<1%	32	$501.05
86787		<1%	42	$466.30
82247		<1%	108	$432.96
84075		<1%	95	$431.57
82248		<1%	120	$380.06
84156		<1%	267	$376.56
85306		<1%	48	$336.50
99000		<1%	36	$281.54
87425		<1%	18	$246.63
81005		<1%	221	$224.12
83880		<1%	14	$218.75
86226		<1%	15	$190.79
82330		<1%	15	$190.70
86225		<1%	15	$175.39
86793		<1%	18	$160.14
86768		<1%	18	$160.14
84144		<1%	18	$152.03
82375		<1%	34	$141.27
87177		<1%	20	$122.97
87070		<1%	27	$121.23
86063		<1%	16	$97.26
87046		<1%	18	$77.65
99072		<1%	1,591	$70.80
84479		<1%	20	$68.72
82947		<1%	13	$48.36
81003		<1%	35	$19.32
99001		0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialQADEER, IMRAN (PRESIDENT)